GlassScriptPhysician profile
Clyde Donald Ford
NPI 1225077084
$4,326.79
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $725 · 2021: $970 · 2022: $1,216 · 2023: $979 · 2024: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133 · Education: $7.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,132.82 |
| Education | $7.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $818.89 | 2019-2024 | Otezla, Repatha, Prolia |
| Lilly USA, LLC | $637.34 | 2020-2024 | Mounjaro, Jardiance |
| Novo Nordisk INC | $633.99 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $381.06 | 2019-2022 | |
| Antares Pharma, INC. | $180.36 | 2020-2024 | Xyosted, Tlando, Nocdurna |
| Glaxosmithkline, LLC. | $151.37 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Pfizer INC. | $141.24 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $100.49 | 2019-2024 | Breztri, Farxiga |
| Bausch Health US, LLC | $92.31 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.46 | 2021-2023 | Trulance, Xifaxan |
| Abbvie INC. | $83.55 | 2021-2023 | |
| Radius Health, INC. | $83.53 | 2020-2023 | Tymlos |
| Merck Sharp & Dohme LLC | $83.34 | 2019-2022 | |
| Astellas Pharma US INC | $66.46 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $65.68 | 2019-2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clyde Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.